Biotech Analyst Schimmer holds a conference call with Chairman & CEO Velleca who will provide an overview of the evolving EGFR mutations (EGFRm) landscape on May 22 at 1 pm hosted by Cantor Fitzgerald. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
- Black Diamond price target lowered to $11 from $12 at H.C. Wainwright
- Black Diamond Therapeutics reports Q1 EPS (35c), consensus (43c)
- Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics announces changes to board of directors
- Black Diamond Therapeutics Revamps Board Leadership
Questions or Comments about the article? Write to editor@tipranks.com